|
Synonyms: CS-0159 | CS0159
Compound class:
Synthetic organic
Comment: Linafexor (CS0159) is a non-bile-acid agonist of the farnesoid X receptor (FXR) [1]. It is designed to mimic the pulsatile nature of physiological bile acid dynamics as an approach to reduce the risk of toxicity arising from sustained drug delivery.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Linafexor (CS0159) was progressed as a clinical candidate for the treatment of liver injury, inflammation, and fibrosis in bile-acid-related diseases. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05082779 | Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159 | Phase 1 Interventional | Cascade Pharmaceuticals, Inc | ||
| NCT05591079 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH | Phase 2 Interventional | Cascade Pharmaceuticals, Inc | ||
| NCT07282353 | A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA | Phase 3 Interventional | Cascade Pharmaceuticals, Inc | ||